Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
KalVista Pharmaceuticals ( (KALV) ) just unveiled an announcement.
KalVista Pharmaceuticals has announced that its 2026 Annual Meeting of Stockholders will be held on June 18, 2026. Due to a change in the meeting date, stockholder proposals for inclusion in the proxy materials must be submitted by January 6, 2026, and other proposals or director nominations must be notified by August 31, 2025, in accordance with the company’s bylaws and the Securities Exchange Act.
The most recent analyst rating on (KALV) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company’s strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock’s score reflects financial struggles counterbalanced by strategic opportunities.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing small molecule protease inhibitors for diseases with significant unmet needs.
Average Trading Volume: 1,218,940
Technical Sentiment Signal: Buy
Current Market Cap: $639.9M
For an in-depth examination of KALV stock, go to TipRanks’ Overview page.